Targeted Protein Degradation Summit

As the drug discovery opportunity hidden within the proteome opens up and gains tremendous investment, the inaugural Targeted Protein Degradation Summit 2018 is a dedicated scientific and networking forum for large pharma, innovative biotech and research institutes to capitalize on this emerging therapeutic class.

Focus on understanding the selectivity and speed of binding, improve the rationale design of bifunctional molecules and overcome critical chemistry challenges to translate these unique small molecules into safe and effective clinical therapeutics.

Built with large pharma and biotech insight, the TPD 2018 is specifically focused on optimizing and accelerating the discovery, translational research and ultimately clinical development of targeted protein degradation therapies across all therapeutic indications.

http://www.proteindegradation.com/

Contact:
info@hansonwade.com
+1 617 455 4188

URLs:
Brochure: https://go.evvnt.com/259077-0?pid=3645
Tickets: https://go.evvnt.com/259077-1?pid=3645

Prices:
Conference + 2 Workshops Earlybird (Book by 17/08/18): USD 3497.0
Conference + 2 Workshops (standard rate): USD 3997.0
Conference + 1 Workshop Earlybird (Book by 17/08/18): USD 2898.0
Conference + 1 Workshop (standard rate): USD 3398.0
Conference Earlybird (Book by 17/08/18): USD 2299.0
Conference (Standard rate): USD 2799.0
Workshop (Only): USD 599.0

Speakers: Craig Crews (Yale University), Alexandra Glucksmann (Cedilla Therapeutics), John Houston (Arvinas), Laurent Audoly (Kymera Therapeutics), John Harling (GSK), Brian Jones (Cedilla Therapeutics)